To include your compound in the COVID-19 Resource Center, submit it here.

Ardelyx gains on Phase III hyperphosphatemia combination data

Ardelyx's tenapanor combination met all endpoints in the Phase III AMPLIFY trial for hyperphosphatemia, setting the stage for a planned 2020 NDA submission once it has long-term monotherapy safety data in hand.

Ardelyx Inc. (NASDAQ:ARDX) jumped 2.42 (71%) to $5.24 Tuesday on AMPLIFY's

Read the full 426 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE